MedTrace Logo

Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

NCT05343832 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4816

Last updated 2022-05-11

No results posted yet for this study

Summary

This trail is a multi-center,prospective observational study aimed to detect early-stage Hepatocellular Carcinoma by a Novel Blood-based DNA Methylation Assay(named Genetron HCC Methylation PCR Kit ). The accuracy of the kit will also be evaluated . The trail will be enroll approximately 4816 participants, including participants with HCC or benign diseases, and high risk factors for liver cancer.

Conditions

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Guangzhou eighth People's Hospital ,Guangzhou Medilcal University

    collaborator UNKNOWN

  • The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology

    collaborator UNKNOWN

  • Ruijin Hospital

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Wuxi No.5 People's Hospital

    collaborator UNKNOWN

  • Peking University First Hospital

    collaborator OTHER

  • Genetron Health

    lead INDUSTRY

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2023-03-05
Completion
2023-04-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05343832 on ClinicalTrials.gov